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Abstract  1 
 2 
Idiopathic epilepsy (IE) is a common chronic neurological disease of the dog. Previous studies 3 
of anti-epileptic drug (AED) treatment have indicated that acceptable AED adverse effects are 4 
as important to owners as reductions in seizure frequency. AEDs in both dogs and humans are 5 
frequently associated with the adverse effect ataxia. The aim of this study was to compare 6 
ataxia levels in dogs with IE treated chronically with phenobarbitone or imepitoin, the two 7 
currently available first-line AED treatments. The gait of six imepitoin-treated dogs, eight 8 
phenobarbitone-treated dogs and ten age-matched healthy control dogs were compared. Fifty 9 
strides from a walking gait were analysed for each dog, quantifying ataxia via the variability 10 
in six established gait parameters. Three variables differed significantly between groups: lateral 11 
distance between (i) pelvic paw placements, (ii) thoracic paw placements and (iii) stance time, 12 
which were significantly more variable in the phenobarbitone-treated dogs than imepitoin-13 
treated or control dogs. These results indicate that dogs treated with phenobarbitone experience 14 
increased ataxia compared to controls and imepitoin-treated dogs. Conversely, there was no 15 
difference between imepitoin-treated dogs and controls. These results along with further 16 
research are needed to quantify AEDs adverse effects, to help vets and owners make more 17 
informed drug-choices. 18 
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Abbreviation  
AED Anti-epileptic drug 
BID Twice a day 
CNS Central Nervous System 
CMSM Chiari like malformation and Syringomyelia 
CV Coefficient of Variation 
IE Idiopathic Epilepsy 
MRI Magnetic Resonance Imaging 
PB Phenobarbitone 
RVC Royal Veterinary College 
QOL Quality of Life 
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Introduction 43 
 44 
Idiopathic epilepsy (IE) is a brain disease characterised by recurrent seizures that is diagnosed 45 
by exclusion of identifiable structural and metabolic causes, and can be of genetic aetiology 46 
(Berendt and others 2015; Thomas 2000). The prevalence of IE within the UK dog population 47 
is reported at 0.62% (Kearsley-Fleet and others 2013), and raw data from the Royal Veterinary 48 
Colleges VetCompass records found that seizures are the third most reported nervous system 49 
presentation in dogs (VetCompass 2016). While prevalence alone indicates the importance of 50 
this disease, IE also has potentially large welfare implications for the affected dog (Packer and 51 
Volk 2015a) and can be distressing for owners to witness and manage (Lord and Podell 1999; 52 
Wessmann and others 2014).  53 
 54 
There are several antiepileptic drugs (AED) available for dogs with IE as monotherapies or 55 
adjunct polytherapies. Phenobarbitone (PB) and imepitoin are two licensed AEDs in the UK, 56 
Australia and most countries in Europe. Both drugs have been demonstrated to have good 57 
efficacy when used as a first-line treatment for dogs with IE (Charalambous and others 2014). 58 
PB has been shown to effectively reduce seizure frequency, but has also been associated with 59 
adverse effects such as sedation, polyphagia, polyuria, polydipsia and ataxia (Tipold and others 60 
2015). Imepitoin has some potential benefits over PB as it has fewer reported adverse effects 61 
and does not require serum level measurements due to its high therapeutic index (Rundfeldt 62 
and Löscher 2014; Tipold and others 2015).  63 
 64 
A study investigating owners’ perception of the adequacy of seizure control, showed that 65 
quality of life (QoL) and acceptable adverse effects of AEDs were just as important to owners 66 
as a reduction in seizure frequency (Chang and others 2006). There is currently a lack of 67 
objective data regarding AED adverse effect profiles (Charalambous and others 2014), 68 
hampering objective choice of AEDs based on both efficacy and adverse effect profile. As 69 
such, there is a strong need for more objective studies of the adverse effects of drugs including 70 
PB and imepitoin. One of the reported adverse effects of PB is ataxia (Tipold and others 2015), 71 
with one survey reporting ataxia in 30% of PB-treated dogs (Chang and others 2006).  72 
 73 
Ataxia is a loss of control of limb coordination and position, which results in delayed and 74 
variable foot placements (Hamilton and others 2007). In human medicine, ataxia or a loss of 75 
balance associated with AEDs has been a focus of study due its association with falls and 76 
skeletal fractures (Fife and Sirven 2005; Gandelman-Marton and others 2006; Mattson and 77 
Gidal 2004). One study found that balance was impaired in epilepsy patients with AEDs  78 
compared to their non-AED treated siblings (Petty and others 2010). As yet, similar studies 79 
objectively assessing the impact of AEDs on gait have not yet been performed in dogs with IE.  80 
 81 
The use of gait analysis to identify or quantify the severity of neurological gait abnormalities 82 
is often carried out using subjective scale systems, such as a 14-point numerical scale assessing 83 
the gait patterns observed (Olby and others 2001). This method is easily implemented in a 84 
clinical setting and has been used to assess the recovery of dogs post spinal surgery successfully 85 
(Olby and others 2004). There are concerns, however, with reproducibility of rating scales due 86 
to their subjective nature (Gordon-Evans and others 2009), observer bias (Arkell and others 87 
2006) and the influence of observer experience on the results (Keegan and others 2010; Keegan 88 
and others 1998). Objective gait measurements are increasingly feasible due to the increased 89 
availability of high definition cameras and relevant computer software. For example, pelvic 90 
limb paw placement was successfully quantified in dogs with spinal cord injury using high 91 
definition motion cameras and markers (Hamilton and others 2007), with increased variability 92 
in lateral paw position seen in dogs with spinal cord injury (Hamilton and others 2008). An 93 
alternative method using high speed recordings of dogs on treadmills revealed lateral instability 94 
and an increase in gait parameter variability in dogs with spinal cord injury (Jeffery and others 95 
2011). Most recently, a combination of using a subjective scale system and high definition 96 
filming has been used to produce continuous data sets for use in future clinical trials in dogs 97 
with spinal cord injury and ataxia, as well as simplistic gait analysis methods to better quantify 98 
ataxia (Olby and others 2014; Song and others 2016; Suiter and others 2013). By formulating 99 
a method that takes into consideration gait parameters such as stride length, lateral paw 100 
placement and step cycle, it may be possible to objectively quantify the presence and degree of 101 
ataxia in dogs being treated with AEDs.  102 
 103 
The aim of this study was to objectively evaluate the gait of dogs with IE being treated with 104 
either PB or imepitoin as monotherapy for canine IE. It is hypothesised that the PB- or 105 
imepitoin-treated dogs will show greater variability in their gait parameters compared to a 106 
healthy control dog population. This is the first known study to quantify gait parameters in 107 
dogs receiving AED therapy, and provides important data on adverse effects.  108 
 109 
Method and Materials 110 
 111 
Recruitment 112 
Dogs were recruited for three separate study groups; healthy control dogs, PB-treated dogs, 113 
and imepitoin-treated dogs. Due to the variation in breed of dogs affected by IE, and the 114 
potential impact of conformation on gait, control dogs were chosen that were close in age and 115 
size to the dogs with epilepsy. Control dogs belonged to vet students and staff from the Royal 116 
Veterinary College (RVC), Hertfordshire, and IE dogs were recruited via social media and 117 
from first opinion small animal vet practices. To be included in the study dogs were required 118 
to meet the following inclusion criteria: 119 
(i) Between 6 months and 10 years of age 120 
(ii) Confirmed by a veterinary surgeon to be free of orthopaedic disease based on 121 
clinical history 122 
(iii) Dogs with IE were required to fit Tier I or Tier II confidence level of IE diagnosis 123 
(De Risio and others 2015). In brief, Tier I dogs had a history of two or more 124 
epileptic seizures with unremarkable inter-ictal physical and neurological 125 
examination with normal bloodwork and urinalysis. Tier II dogs had the same 126 
findings as Tier 1 with added diagnostics revealing normal brain MRI findings, 127 
unremarkable bile acids and unremarkable cerebrospinal fluid analysis.   128 
(iv) Dogs with IE were required to have been treated with PB or imepitoin as a 129 
monotherapy for at least 2 weeks prior to the study. 130 
All owners who volunteered their dogs were provided with an owner information sheet (RVC 131 
Animal Welfare and Ethics Committee reference 2015/T334) explaining the study protocol and 132 
signed a consent form to allow their dogs involvement in the study. 133 
Gait analysis 134 
 135 
 136 
Motion capture was performed in the structure and motion lab situated at the RVC and at 137 
owner’s homes if they could not travel. Two digital stills cameras (Nikon 1-J1 model) capable 138 
of full high definition video capture were used. Both cameras were set up over 1m away from 139 
the walkway mat in order to capture both a front on, and lateral view of the dogs. The dogs 140 
were walked over-ground along an 8 m runway with black electrical tape marking up 0.5 x 141 
0.5m squares into a 0.5 x 5 m grid made up of black tape on a flat surface. Cameras and the 142 
runway mat were fully portable so could be taken to owners’ houses if required. The mat was 143 
placed on a flat and solid surface and the camera set-up was as described above. Both cameras 144 
were set to film in full high definition, pixel 1920x1080 at 60fps, shutter speed 1/1250. Owners 145 
were then asked to walk their dog at their own comfortable walking gait on the lead. Owners 146 
were advised on how best to walk their dog along the runway, ensuring the dog remained within 147 
the mat at all times during the walk. Dogs did not require any training or markers on their 148 
bodies to be filmed. If a dog transitioned into another gait (e.g. trot or pace), stopped or became 149 
distracted during a walk, the filming was aborted and the walk repeated. 50 strides were 150 
collected in order to increase the reliability and statistical power of the results, and is similar 151 
or in excess of the number of strides used in other gait studies analysing ataxia in dogs 152 
(Hamilton and others 2007; Ishihara and others 2009; Jeffery and others 2011) 153 
 154 
Parameters measured were chosen based on parameters measured in other neurological gait 155 
studies (Hamilton and others 2007; Jeffery and others 2011; Olby and others 2014) and are 156 
summarised in Table 1. These parameters were measured post-filming using the recorded 157 
footage, assessing each dog’s gait using Quintic Video Analysis Software (Quintic 158 
Consultancy Ltd, West Midlands, UK). To analyse paw placements, freeze frames were taken 159 
at points where a paw was fully on the ground. This was performed with footage from both 160 
cameras and was performed for every foot for all strides taken. Once all the frames were 161 
collected, images were opened with software ‘Image J’ (ImageJ 2012). Image J allowed a scale 162 
to be set for the grid, so the image coordinates (pixels) matched real life coordinates (cm) and 163 
chosen parameters were measured using the straight line tool.  164 
 165 
Statistical analysis 166 
 167 
Data were collated in Microsoft Excel 2010 (Microsoft Corp, Redmond, WA, US) then 168 
analysed using GraphPad Prism (Version 5, ©1992-2010 GraphPad Software, Inc.) for 169 
univariate analysis, and IBM SPSS Statistics (Version 19, Armonk, NY: IBM Corp) for 170 
multivariate analysis. For each gait parameter the mean and standard deviation was calculated, 171 
along with the coefficient of variation (CV = standard deviation / mean). CV is a unit-less 172 
parameter which quantifies the spread of data relating to the variability of a parameter. A higher 173 
CV value indicates more variable data. By examining only the variability of the individual’s 174 
gait, and not the exact parameter measurements, differences between study subjects cannot be 175 
simply attributed to variation in size or conformation. Instead, the CV values focus on 176 
coordination consistency of the individual (Hamilton and others 2008). 177 
 178 
CV values were checked for normality of distribution, then groups were statistically compared 179 
at the univariate level using the non-parametric Kruskal-Wallis test, with summary statistics 180 
stated as medians and 25th-75th percentiles. If the Kruskall-Wallis test discovered significant 181 
differences between the groups, a post-hoc Dunn’s test was performed to determine which 182 
groups differed from each other. Linear mixed models were then created to further analyse the 183 
association between treatment group and gait parameters. The CV of gait parameters were 184 
included as outcome measures, with the random effect of dog ID included in all models to take 185 
into account individual variation between dogs, with the fixed effect of medication group 186 
(imepitoin, PB, or control). A p-value of less than 0.05 was considered significant in all tests.  187 
 188 
Results 189 
 190 
Twenty-four dogs were recruited; healthy control dogs (n=10), PB-treated dogs with IE (n=8), 191 
and imepitoin-treated dogs with IE (n=6). Details of the dogs recruited are summarised in Table 192 
2. Ages of the dogs did not significantly differ between groups. 193 
 194 
Gait analysis 195 
 196 
CV of two of the six gait parameters measured were found to significantly differ between 197 
groups at the univariate level, CV of pelvic paw distance and thoracic paw distance. CV of 198 
pelvic and thoracic paw distance was found to differ significantly between the following study 199 
groups, with the PB group showing a significantly higher variability in pelvic paw distance 200 
compared to the control group and imepitoin-treated group (Figure 1 and 2, and Table 3). There 201 
were, however, no significant differences between the CV of thoracic or pelvic paw distance 202 
between the control and imepitoin groups. No significant differences were found between the 203 
groups at the univariate level for the CV of step time, stance time, stride length and ipsilateral 204 
distance (Table 3). 205 
 206 
When individual dog variation was accounted for in a linear mixed model, including dog ID as 207 
a random effect, CV of pelvic paw distance and thoracic paw distance remained significantly 208 
different between groups, with higher variability seen in the PB group compared to controls. A 209 
further association was found between CV of stance time and treatment group, with the PB 210 
group significantly more variable compared to controls (Figure 3 and Table 4).  211 
 212 
  213 
Discussion 214 
 215 
This study aimed to evaluate the variability of gait in dogs with IE treated with either PB or 216 
imepitoin, in order to quantify the adverse effect ataxia. To the authors’ knowledge this is the 217 
first time the gait of dogs treated for IE has been objectively quantified. The method described 218 
in this study could quantify an increase in paw placement variability, as reflected in our results. 219 
Previous studies quantifying ataxia in dogs have used treadmills to maintain speed and remove 220 
variables such as direction change or handler error (Gordon-Evans and others 2009; Hamilton 221 
and others 2007, 2008; Olby and others 2014). Using trademills is not without problems, and 222 
if time is not spent habituating animals on the treadmill this can severely alter results (Clements 223 
and others 2005) and is also time and training intensive (Buchner 1994). By using the method 224 
described in this study, walking in a familiar on-lead manner on a walkway, error due to 225 
unfamiliarity and/or anxiety is reduced and is feasible for the owner and researchers to 226 
complete. Collecting data at owners’ homes also had the benefit of allowing dogs to be in their 227 
familiar environments, which is expected to reduce anxiety. Anxiety in novel environments 228 
may affect gait as dogs may exhibit behaviours such as an inability to settle, seeking exit or 229 
attempting to walk closer to their owners for security. A limitation of our study design is that 230 
the analyser for the study also recruited the dogs, and therefore was not completely blinded. 231 
However, analysis of gait was temporally apart from video capture and gait parameter 232 
measurements were objective using a consistent measurement technique.  233 
 234 
A wide variety of breeds were recruited for this study, due to epilepsy affecting many breeds 235 
(Hülsmeyer and others 2015); however, this may be considered a limitation due to potentially 236 
significant variation in gait between breeds related to size, weight and conformation. To reduce 237 
this potential effect, we examined the CV of the individual dog’s gait parameters rather than 238 
the raw values. CV has been used to summarise the variability of foot placement during 239 
movement to quantify ataxia in people (Dubost and others 2008), dogs (Hamilton and others 240 
2008) and horses (Olsen 2015). Hamilton and others (2008) interpreted an increase in CV 241 
values for pelvic and thoracic paws distance to be related to the inability of a dog to place their 242 
feet back into the correct lateral plane due to their ataxia. As we were able to also show a 243 
significant increase in CV values for the PB treated dogs, which we expected to be ataxic, this 244 
is supportive that our method can detect ataxia.  A more recent study looking into simplified 245 
gait analysis of dogs’ post-spinal cord injury (Song and others 2016) found that the CV of 246 
‘Base of Support’ in pelvic and thoracic limbs (similar measurement to lateral distance used in 247 
this study) did not significantly differ between normal dogs and those with spinal cord injury. 248 
However, dogs with spinal cord injury typically have asymmetrical spinal lesions which can 249 
allow for compensation. In contrast, dogs treated with antiepileptic drugs are expected to have 250 
symmetrical deficits, due to an increase in the action of GABA (Podell 1998). This could be 251 
altering the proprioceptive pathways and their central processing, due to unspecific targeting 252 
within the CNS.  253 
 254 
The results of this study indicate that being treated with PB affects the gait of dogs with IE. 255 
This is similar to previous findings in people (Fife and Sirven 2005; Gandelman-Marton and 256 
others 2006; Petty and others 2010) although not directly replicated. Dogs treated with PB were 257 
shown to have a significantly higher variability in their lateral paw placements (pelvic paw 258 
distance and thoracic paw distance) and stance, suggesting an inability to coordinate their paw 259 
positioning whilst walking when compared to the imepitoin treated dogs and control dogs. This 260 
finding supports our initial hypothesis, and provides objective support for the observation that 261 
PB causes ataxia in dogs with IE, as previously reported by owners and clinicians (Chang and 262 
others 2006; Dayrell-Hart and others 1991; Tipold and others 2015). In comparison, the 263 
imepitoin-treated groups had very similar CV values to the control group. By having CV values 264 
as low as the control groups, we can assume that this is because the imepitoin treated dogs 265 
show little to no signs of ataxia.  This is likely due to imepitoin‘s  mechanism of action. 266 
Imepitoin is a partial agonist of GABAA receptors, and acts on the benzodiazepine site which 267 
only modulates the GABA effect, rather than directly activating the receptor (Tipold and others 268 
2015).  By having a much lower intrinsic activity in comparison to PB, this could explain why 269 
ataxia and other adverse effects are seen less often (Rundfeldt and Löscher 2014) and why we 270 
found no difference to our control group CV values. 271 
 272 
CV of step time was not found to differ between treatment groups in any analysis. CV of stance 273 
time variability did not differ between treatment groups in the univariate analysis. However, 274 
when the non-independence introduced by individual dog variation was accounted for in a 275 
mixed effects model, CV of stance time was significantly more variable in PB treated dogs 276 
compared to controls. Step time and stance time have been found to be significantly reduced 277 
in mice with spinal cord injury (Beare and others 2009) as well as in ataxic dogs (Gordon-278 
Evans and others 2009). The PB treated dogs in this study did not have reduced stance time, 279 
but more variable stance time during their walking gait, which could be explained by the large 280 
variability from stride to stride. In combination with the lateral paw placement variability, we 281 
can expect that with some wide and some narrow strides, there will be varying times that the 282 
opposing paw will be kept on the ground in order to remained balanced during the walk. The 283 
other measured parameters did not show a change in variability between the three groups. 284 
Ipsilateral paw distance variability has only previously been measured in one study, where the 285 
gait of Cavalier King Charles Spaniels with Chiari-like malformation and Syringomyelia 286 
(CMSM) was studied. That study showed a significantly higher variability in ipsilateral paws 287 
distance compared to a group of similarly-sized control dogs (Suiter and others 2013). In this 288 
study, PB-treated dogs did not show this, which may be explained by the diffuse effect of PB 289 
on the CNS compared to a more localised pathology seen in dogs with CMSM. Stride length 290 
variability did not differ between groups, which was unexpected as an uncoordinated gait with 291 
a combination of long and short strides may be expected due to altered balance during the walk. 292 
It is likely that to see an increase in stride length variability, the dogs would have observable 293 
ataxia, as this is what has been found in previous ataxia studies (Hamilton and others 2008; 294 
Olby and others 2014; Gordon-Evans and others 2009). The PB treated dogs in this study were 295 
not reported to have ataxia by the owners, and often it is dogs who are in the first month of PB 296 
administration that show the most ataxia (Boothe and others 2012). As our dogs were 297 
chronically treated with phenobarbitone, they have had time to adjust to the drug activity and 298 
therefore only show mild ataxia which the owners might notice anymore subjectively but can 299 
be picked up by more objective assessment techniques. As well as this, previous ataxia studies 300 
(Hamilton and others 2008; Olby and others 2014; Gordon-Evans and others 2009) have looked 301 
at localised spinal pathology rather than at a diffuse reduction in  CNS activity.  302 
 303 
The PB group had a much wider range in CV values as well as higher mean CV values. This 304 
may indicate that PB treatment affects individuals to different extents, with variation in the 305 
presence and severity of ataxia. An owner survey found that PB-treated dogs had a reported 306 
ataxia incidence of 30% (Chang and others 2006), and thus not all dogs might be affected by 307 
this adverse effect or more likely owners do not recognise the adverse-effect ataxia. As 308 
aforementioned within this study none of the owners of the IE dogs declared ataxia as a problem 309 
in their dogs’ lives. Two PB treated dogs were no longer achieving fast times in agility training, 310 
however the owners were confident their dogs’ QoL was not affected. Further research into 311 
how PB serum levels correlate with ataxia severity would be worthwhile and it would be 312 
interesting to understand owner’s subjective thresholds for reporting ataxia in their dogs. 313 
Further research is also required to compare the prevalence and severity of ataxia seen with 314 
different AEDs available to treat dogs with IE, or of different combinations of AEDs, as many 315 
IE affected dogs require more than one AED to control their seizures (Packer and others 2015b; 316 
Platt and others 2006; Schwartz-Porsche and others 1985; Thomas 2000). Quantifying AED 317 
adverse effects is an important area of study, as IE affected dogs are treated with these 318 
medications chronically due to IEs lifelong nature, and the relative rarity of remission (Packer 319 
and others 2014). This means that chronic adverse effects may have a large and lasting impact 320 
on the QoL of the treated dog and their owner. The more that is understood about AED adverse 321 
effects, which drugs they are most commonly associated with, and which dogs are most likely 322 
to be affected by them, the more vets will be able to offer a more tailored approach to IE 323 
treatment, to best suit the individual patient. 324 
 325 
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Table 1: Descriptors for each gait parameter measured 
Stride Parameter Descriptor 
Step Time Time between the toe of the paw coming off the ground and then the same 
paw being placed back on the ground. Measured in seconds. 
Stance Time Time between foot landing on the ground and then the same paw being 
lifted off the ground into another stride. Measured in seconds. 
Stride Length The distance from where the toe of the paw of interest leaves the ground 
and where the same foot subsequently lands during walk. Measured in cm. 
Ipsilateral Paw Distance The lateral distance between the thoracic limb paw placement and the 
ipsilateral pelvic limb paw placement during the walk. Measured in cm. 
Pelvic Paw Distance The distance between the placement of the left pelvic limb paw and the 
subsequent right pelvic limb paw placement. Measured in cm. 
Thoracic Paw Distance The distance between the placement of the left thoracic limb paw and the 
subsequent right thoracic limb paw placement. Measured in cm. 
 
 
 
 
 
 
 
 
 
  
Table 2: Signalment and clinical characteristics of dogs enrolled in this study 
Dog ID Age Breed 
IE Tier and 
Diagnosis 
Year 
Time 
treated/ 
months 
Dose / 
mg/kg BID 
Serum 
Levels / 
μg/ml 
Control        
C1 5.5y Northern Inuit     
C2 5y Labrador Cross     
C3 9y Terrier Cross     
C4 2y Collie Cross      
C5 6y Terrier Cross     
C6 2y Chihuahua     
C7 6y Jack Russell     
C8 3y Labrador Cross     
C9 3y Kooikerhondje     
C10 4y Rottweiler     
Mean ± SE 4.5±2.0      
Imepitoin       
I1 6y Lurcher Tier II 2012 30 22.5  
I2 9y Jack Russell Tier I 2012 24 10  
I3 7y Jack Russell Tier 1 2014 12 10  
I4 5y Parsons Jack Russell Tier II 2015 1 10  
I5 6m Dogue De Bordeaux Tier II 2015 1 30  
I6 4y Chinese Crested Tier I 2015 5 20  
Mean ± SE 5.3±1.3   12.2±3.5 17.1±2.0  
PB       
P1 4y Northern Inuit Tier II 2013 24 2.5 24 
P2 3y Old English Sheepdog Tier II 2013 22 2.5 25 
P3 4y Whippet Tier I 2014 10 2.5 21 
P4 3y Long Haired Daschund Tier II 2013 22 1 20 
P5 4y Parsons Jack Russell Tier II 2014 12 2.5 22.1 
P6 6y Lurcher Tier II 2012 20 2 15.6 
P7 4y Belgian Shepherd Tier II 2012 32 2.5 32 
P8 5y Jack Russell Tier II 2013 15 2 28.2 
Mean ± SE 4.1±1.0   19±1.6 2.2±0.5 23.5±1.04 
SE=Standard Error of the Mean, ID=Identity, IE=Idiopathic Epilepsy, BID=”bis in die” (twice daily) 
 
 
 
 
 
Table 3: Gait parameters compared between treatment groups. Coefficient of Variation 
(CV) of thoracic and pelvic paw distance were found to differ significantly between the 
following study groups, with the PB group showing a significantly higher variability in thoracic 
and pelvic paw distance compared to the control group and imepitoin-treated group.  
Groups Step Time Stance Time Stride 
Length 
Ipsilateral 
Distance 
Pelvic Distance Thoracic 
Distance 
N (total steps 
analysed) 
485 485 458 376 530 530 
Control 
(n=10) 
 
0.106  
(0.063-0.129) 
0.101  
(0.071-0.127) 
0.07  
(0.035-0.079) 
0.08  
(0.043-0.088) 
0.168  
(0.119-0.175) 
0.157  
(0.126-0.164) 
Imepitoin 
(n=6) 
 
0.12  
(0.066-0.142) 
0.1  
(0.068-0.131) 
0.084  
(0.051-0.104) 
0.077 
 (0.048-0.086) 
0.125  
(0.097-0.181) 
0.160  
(0.081-0.172) 
PB 
(n=8) 
0.1 
(0.067-0.105) 
0.149  
(0.101-0.207) 
0.086  
(0.061-0.091) 
0.076 
 (0.053-0.100) 
0.299  
(0.197-0.327)*+ 
0.293  
(0.238-0.389)*+ 
Data are presented as median (25th – 75th percentile) of CV values from all groups. Univariate comparison 
between the groups was carried out by a Dunn’s Multiple Comparison Test where a p value <0.05 was deemed 
significant (* = significant difference to control group; + = significant difference to imepitoin group). 
 
 
 
 
 
 
 
  
Table 4: Linear mixed model investigating the effect of treatment group on gait 
parameters, including individual dog as a random effect. Coefficient of Variation of stance 
time, pelvic paw distance and thoracic paw distance differed significantly between groups, with 
higher variability seen in the phenobarbitone (PB) group compared to controls.  
Variable Stance Time  Pelvic Distance  Thoracic 
Distance 
 
 CV (±SE) P CV (±SE) P CV (±SE) P 
Intercept 0.108 (± 0.033) 0.003* 0.160 (± 0.039) 0.001* 0.159 (± 0.055) 0.008* 
Imepitoin 0.001 (± 0.021) 0.952 -0.016 (± 0.025) 0.536 -0.011 (± 0.036) 0.770 
PB 0.043 (± 0.020) 0.046* 0.134 (± 0.024) <0.001* 0.168 (± 0.034) <0.001* 
Control ref 
Coefficient of Variation (CV) ± Standard Error (SE) values from the treatment groups, using the control group 
for reference. *Linear mixed model with p<0.05 deemed significant. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  
 
Box and whisker plots showing the comparison of pelvic paw distance Coefficient of 
Variation between the three study groups. Coefficient of Variation (CV) of pelvic paw 
distance was found to differ significantly between the following study groups, with the 
Phenobarbitone group showing a significantly higher variability in thoracic and pelvic paw 
distance compared to the control group and imepitoin-treated group. The upper and lower 
percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through 
each box (*p<0.05 and **p<0.01). 
 
Figure 2: 
  
Box and whisker plots showing the comparison of thoracic paw distance coefficient of 
variation between the three study groups. Coefficient of Variation (CV) of thoracic paw 
distance was found to differ significantly between the following study groups, with the 
Phenobarbitone group showing a significantly higher variability in thoracic and pelvic paw 
distance compared to the control group and imepitoin-treated group. The upper and lower 
percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through 
each box (*p<0.05 and **p<0.01). 
 
Figure 3:  
 
Box and whisker plots showing the comparison of stance time Coefficient of Variation 
between the three study groups. Coefficient of Variation (CV) of stance time was found to 
differ significantly between the following study groups, with the Phenobarbitone group 
showing a significantly higher variability compared to the control group. The upper and lower 
percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through 
each box. One asterix (*) represents significance of p<0.05 following a linear mixed model 
analysis. 
 
